Sangamo BioSciences Reports Second Quarter 2008 Financi...(and businessenvironments. These risks an...)

Date:7/23/2008

and business environments. These risks and uncertainties are described more fully in Sangamo's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q as filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.

SELECTED FINANCIAL DATA

(in thousands, except per share data)

(unaudited)

Three Months Ended Six Months Ended

June 30, June 30,

2008 2007 2008 2007

Consolidated Statement of

Operations Data:

Revenues

Collaboration agreements $2,378 $1,461 $4,462 $2,611

Research grants 464 1,123 1,145 1,395

Total revenues 2,842 2,584 5,607 4,006

Operating expenses:

Research and development 8,286 6,309 16,929 11,739

General and administrative 2,545 2,113 5,472 4,112

Total operating expenses 10,831 8,422 22,401 15,851

Loss from operations (7,989) (5,838) (16,794) (11,845)

Interest income, net 570 657 1,406 1,305

Net loss $(7,419) $(5,181) $(15,388) $(10,540)

Basic and diluted net loss per

common share $(0.18) $(0.15) $(0.38) $(0.30)

Shares used in computing basic and

diluted net loss per common share 40,858 35,136 40,673 35,097

CONSOLIDATED CONDENSED BALANCE SHEET

DATA

June 30, 2008 December 31, 2007

Cash, cash equivalents, and

investments $64,295 $81,412

Total assets
'/>"/>

SOURCE Sangamo BioSciences, Inc. Copyright©2008 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5 6 7 8
Related biology technology :

1. Sangamo BioSciences Announces Second Quarter Conference Call and Webcast
2. Sangamo BioSciences and Sigma-Aldrich Announce Research and License Agreement With Roche for the Use of ZFN Technology for Generation of Transgenic Animals
3. Dow AgroSciences Announces Early Exercise of Option for Commercial License With Sangamo BioSciences for Plants
4. Dow AgroSciences, Sangamo BioSciences Announce the Achievement of Key Milestones in Plant Agriculture Collaboration
5. Sangamo BioSciences to Present at the Canaccord Adams Diabetes and Obesity Conference
6. Sangamo BioSciences Announces Presentation of Phase 1 Data of ZFP Therapeutic at International Society for Cellular Therapy (ISCT) Meeting
7. Sangamo BioSciences Nominates Thomas G. Wiggans to Its Board of Directors
8. Sangamo BioSciences Announces First Quarter Conference Call and Webcast
9. Sangamo BioSciences Announces License Agreement For the Use of ZFP Technology For Generation of Transgenic Animals
10. Sangamo BioSciences to Present at the Cowen and Company 28th Annual Health Care Conference
11. Sangamo BioSciences Announces Expansion of Research and License Agreement With Genentech for ZFP Technology for Protein Pharmaceutical Production